SLC16A3 and neoplasm: Its target specificity and in vivo efficacy have been further supported by multiple independent studies, in which MSC-4381 effectively blocked SLC16A3-mediated lactate oxidation and suppressed tumor progression without detectable off-target effects (37, 38).